Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1988 Jan 1;138(1):51–53.

Neuroleptic malignant syndrome.

G A Chaimowitz 1, U Gomes 1, S S Maze 1
PMCID: PMC1267509  PMID: 3275480

Full text

PDF
51

Images in this article

53Fig. 1
on p.53

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birkhimer L. J., DeVane C. L. The neuroleptic malignant syndrome: presentation and treatment. Drug Intell Clin Pharm. 1984 Jun;18(6):462–465. doi: 10.1177/106002808401800601. [DOI] [PubMed] [Google Scholar]
  2. Burke R. E., Fahn S., Mayeux R., Weinberg H., Louis K., Willner J. H. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology. 1981 Aug;31(8):1022–1025. doi: 10.1212/wnl.31.8.1022. [DOI] [PubMed] [Google Scholar]
  3. Caroff S. N. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980 Mar;41(3):79–83. [PubMed] [Google Scholar]
  4. Cohen W. J., Cohen N. H. Lithium carbonate, haloperidol, and irreversible brain damage. JAMA. 1974 Dec 2;230(9):1283–1287. [PubMed] [Google Scholar]
  5. Granato J. E., Stern B. J., Ringel A., Karim A. H., Krumholz A., Coyle J., Adler S. Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. Ann Neurol. 1983 Jul;14(1):89–90. doi: 10.1002/ana.410140117. [DOI] [PubMed] [Google Scholar]
  6. Greenberg L. B., Gujavarty K. The neuroleptic malignant syndrome: review and report of three cases. Compr Psychiatry. 1985 Jan-Feb;26(1):63–70. doi: 10.1016/0010-440x(85)90050-1. [DOI] [PubMed] [Google Scholar]
  7. Guzé B. H., Baxter L. R., Jr Current concepts. Neuroleptic malignant syndrome. N Engl J Med. 1985 Jul 18;313(3):163–166. doi: 10.1056/NEJM198507183130306. [DOI] [PubMed] [Google Scholar]
  8. Henderson V. W., Wooten G. F. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology. 1981 Feb;31(2):132–137. doi: 10.1212/wnl.31.2.132. [DOI] [PubMed] [Google Scholar]
  9. Itoh H., Ohtsuka N., Ogita K., Yagi G., Miura S., Koga Y. Malignant neuroleptic syndrome--its present status in Japan and clinical problems. Folia Psychiatr Neurol Jpn. 1977;31(4):559–576. [PubMed] [Google Scholar]
  10. Kurlan R., Hamill R., Shoulson I. Neuroleptic malignant syndrome. Clin Neuropharmacol. 1984;7(2):109–120. doi: 10.1097/00002826-198406000-00001. [DOI] [PubMed] [Google Scholar]
  11. Levenson J. L. Neuroleptic malignant syndrome. Am J Psychiatry. 1985 Oct;142(10):1137–1145. doi: 10.1176/ajp.142.10.1137. [DOI] [PubMed] [Google Scholar]
  12. Mann S. C., Boger W. P. Psychotropic drugs, summer heat and humidity, and hyperpyrexia: a danger restated. Am J Psychiatry. 1978 Sep;135(9):1097–1100. doi: 10.1176/ajp.135.9.1097. [DOI] [PubMed] [Google Scholar]
  13. Meltzer H. Y. Rigidity, hyperpyrexia and coma following fluphenazine enanthate. Psychopharmacologia. 1973;29(4):337–346. doi: 10.1007/BF00429281. [DOI] [PubMed] [Google Scholar]
  14. Neppe V. M. The neuroleptic malignant syndrome. A priority system. S Afr Med J. 1984 Mar 31;65(13):523–525. [PubMed] [Google Scholar]
  15. Smego R. A., Jr, Durack D. T. The neuroleptic malignant syndrome. Arch Intern Med. 1982 Jun;142(6):1183–1185. [PubMed] [Google Scholar]
  16. Tollefson G. A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia. J Clin Psychopharmacol. 1982 Aug;2(4):266–270. [PubMed] [Google Scholar]
  17. Weinberger D. R., Kelly M. J. Catatonia and malignant syndrome: a possible complication of neuroleptic administration. Report of a case involving haloperidol. J Nerv Ment Dis. 1977 Oct;165(4):263–268. [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES